title: Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye.
abstract: Antisense oligonucleotides (ODNs) specific for VEGFR-2-(17 MER) and inhibiting HUVEC proliferation in-vitro were screened. One efficient sequence was selected and incorporated in different types of nanoemulsions the potential toxicity of which was evaluated on HUVEC and ARPE19 cells. Our results showed that below 10 microl/ml, a 2.5% mid-chain triglycerides cationic DOTAP nanoemulsion was non-toxic on HUVEC and retinal cells. This formulation was therefore chosen for further experiments. In-vitro transfection of FITC ODNs in ARPE cells using DOTAP nanoemulsions showed that nanodroplets do penetrate into the cells. Furthermore, ODNs are released from the nanoemulsion after 48 h and accumulate into the cell nuclei. In both ex-vivo and in-vivo ODN stability experiments in rabbit vitreous, it was noted that the nanoemulsion protected at least partially the ODN from degradation over 72 h. The kinetic results of fluorescent ODN (Hex) distribution in DOTAP nanoemulsion following intravitreal injection in the rat showed that the nanoemulsion penetrates all retinal cells. Pharmacokinetic and ocular tissue distribution of radioactive ODN following intravitreal injection in rabbits showed that the DOTAP nanoemulsion apparently enhanced the intraretinal penetration of the ODNs up to the inner nuclear layer (INL) and might yield potential therapeutic levels of ODN in the retina over 72 h post injection.
authors.affiliation: Department of Pharmaceutics, The School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
authors.forename: Tal
authors.initials: T
authors.lastname: Hagigit
authors.forename: Muhammad
authors.initials: M
authors.lastname: Abdulrazik
authors.forename: Faik
authors.initials: F
authors.lastname: Orucov
authors.forename: Faty
authors.initials: F
authors.lastname: Valamanesh
authors.forename: Martin
authors.initials: M
authors.lastname: Hagedorn
authors.forename: Martin
authors.initials: M
authors.lastname: Lambert
authors.forename: Gregory
authors.initials: G
authors.lastname: Lambert
authors.forename: Francine
authors.initials: F
authors.lastname: Behar-Cohen
authors.forename: Simon
authors.initials: S
authors.lastname: Benita
mesh_terms: D000287:Administration, Topical; D000818:Animals; D002412:Cations / Q000737:chemistry; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival; D004655:Emulsions / Q000737:chemistry* / Q000378:metabolism; D005123:Eye / Q000378:metabolism*; D006801:Humans; D008297:Male; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics; D011817:Rabbits; D051381:Rats; D011917:Rats, Inbred Lew; D013873:Thionucleotides / Q000008:administration & dosage; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics*
chemical_list: D002412:Cations; D004655:Emulsions; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; D040301:Vascular Endothelial Growth Factor Receptor-2